ClinicalTrials.gg
RecruitingNCT06199180REPEAT-AFUpdated Dec 10, 2024

Pulsed Field Ablation Versus Conventional Radiofrequency Catheter Ablation for Repeat PVI in Patients With Paroxysmal AF

An interventional study of pulmonary vein isolation with RFA and pulmonary vein isolation with PFA in Atrial Fibrillation Recurrent, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Atrial Fibrillation by University Medical Center Groningen — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · University Medical Center Groningen.

Planned enrollment
8th of 13
154 · median 220
Started
2024
with 3 others
No phase
9 of 16
3 open now
Registered
13th of 16
by date

Among the 16 studies in Atrial Fibrillation by University Medical Center Groningen, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 with no phase, and was the 13th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 16 studies in Atrial Fibrillation by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by University Medical Center Groningen, or all of them as a file.
02

Study summary

Various methods exist for performing pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF), including thermal ablation and pulse-field ablation (PFA). However, in cases requiring a second PVI for recurrent AF, radiofrequency ablation (RFA) is utilized in nearly 95% of instances post-acquiring a 3D high-density map from the left atrium (LA). Up to 85% of patients experiencing recurrent AF after the initial PVI exhibit pulmonary vein (PV) reconnections, often identified as the cause of AF.

PFA has demonstrated its safety and efficiency compared to RFA as a swift technique for performing ablation. Yet, whether PFA or RFA stands out as superior or safer when applied for a second PVI remains unclear, as no randomized controlled trial has investigated this comparison. The proposed REPEAT-AF trial aims to randomize 154 AF patients experiencing recurrent AF after the initial PVI, assigning them in a 1:1 ratio to either RFA or PFA. Each patient will receive an implantable cardiac monitor to precisely detect any AF recurrences.

Read the detailed description

All participating patients are required to provide written (or equivalent) informed consent, indicated by a dated signature of the subject or legal representative. The consent process must comply with applicable national regulations and use language understandable by the patient.

The study will be conducted at 6 clinical centres/investigational sites across the Netherlands. Patients will be randomized (1:1) into a PFA or point-by-point RF ablation arm. Randomization will occur prior to the ablation procedure. A implantable cardiac monitor will be implanted in all randomised patients one month before ablation to accurately monitor any AF/atrial flutter (AFL)/ atrial tachycardia (AT) recurrence. Treatment allocation will be processed through the Dutch 'National Heart Registry' (NHR) data platform.

Patients randomized to both arms of the study will be evaluated for PV isolation at the start of the ablation procedure. If PV reconnection is identified in patients in the point-by-point RF arm, re-ablation will occur according to the study protocol. Patients in the PFA arm will have PV reconnection determined using the FARAWAVE catheter. Those with no PV reconnection (100% PV isolation/durable PVI) will be followed in an observational registry.

The PFA ablation arm involves the use of the Farastar generator system, Farawave ablation catheter, and Faradrive steering catheter for the procedure. The RF point-by-point ablation arm (control) involves RF ablation following standard practice.

03

Conditions studied

  • Atrial Fibrillation Recurrent

Browse trials for

Keywords

  • pulmonary vein isolation
  • pulsed field ablation
  • radiofrequency ablation
  • implantable cardiac monitor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects who meet all of the following inclusion criteria at screening will be eligible for enrolment:

  • Patient had 1 previous PVI with either cryoballoon, RF ablation or PFA
  • Index PVI occurred within \<5 years prior to enrolment
  • Documented AF recurrence >30 seconds
  • Symptomatic AF
  • Paroxysmal AF
  • Age >18 and \<80 years
  • Willing and capable to provide
  • Able and willing to participate in all examinations and follow-up visits and tests associated with this clinical study

Subjects who meet ANY of the following exclusion criteria will be excluded from the study:

  • Persistent AF (by diagnosis of duration >7 days)
  • Concomitant/ prior diagnosis for atrial tachycardia (AT) and/or atrial flutter (AFl). Note typical cavotricuspid isthmus dependent flutter is not an exclusion criterium.
  • Underwent additional ablations outside the pulmonary veins during index AF ablation
  • AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other reversible/non-cardiac causes
  • to, or unwillingness to use, systematic anticoagulation
  • (LVEF) \<30% as documented by transthoracic echo (TTE) (within \<3 months prior)
  • Left atrial volume index >60 ml/m2
  • arrhythmias other than AF
  • Previous surgery for AF
  • (NYHA) Functional Class III or IV
  • Presence of intramural thrombus, tumour or other abnormality that precludes safe catheter introduction or manipulation
  • >35 kg/m2
  • Significant or symptomatic hypotension, bradycardia, or chronotropic incompetence
  • Chronic renal insufficiency of \<15 mL/min/1.73 m2 or any history of renal dialysis, or history of renal transplant
  • Hemodynamically significant valvular disease
  • Presence of patent foramen ovale (PFO) or atrial septal defect (ASD) closure device
  • History of abnormal bleeding and/or clotting disorder
  • History of rheumatic fever
  • Severe lung disease, pulmonary hypertension, or any lung disease. Only if involving abnormal blood gases or significant dyspnoea
  • Clinically significant systemic infection or sepsis
  • \<1 year
  • Sensitivity to contrast media not controlled by pre-medication
  • Any of the following within the 3 months prior to enrolment:

    • Myocardial infarction
    • Unstable angina
    • Percutaneous coronary intervention
    • Heart failure hospitalization
    • Stroke or
    • Significant bleeding
    • Pericarditis/effusions
    • Left atrial thrombus
  • Coronary artery bypass grafting/atriotomy within 6 months prior
  • Organ or haematologic transplant, or currently being evaluated for an organ transplant
  • Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
154 participants (estimated)

Study arms

  • Active comparator
    Radiofrequency ablation

    In this group, patients will undergo the acquisition of a 3D high-density map. If pulmonary vein (PV) reconnection is identified, radiofrequency ablation (RFA) will be employed for pulmonary vein isolation (PVI). Should PV reconnection not be detected, the operator will have the discretion to determine the necessary ablation strategies. Patients falling into this category will be included in a concurrent registry.

    Device: pulmonary vein isolation with RFA

  • Experimental
    Pulsed field ablation

    In this group, pulmonary vein (PV) reconnection is identified by the FARAWAVE system. If reconnection is observed, pulsed field ablation (PFA) will be employed for pulmonary vein isolation (PVI). Should PV reconnection not be detected, the operator will have the discretion to determine the necessary ablation strategies. Patients falling into this category will be included in a concurrent registry.

    Device: pulmonary vein isolation with PFA

Interventions

  • Devicepulmonary vein isolation with RFA

    Patients randomised to RFA will undergo PVI with point-by-point RFA.

  • Devicepulmonary vein isolation with PFA

    Patients randomised to PFA will undergo PVI with PFA.

06

What researchers measure

Primary outcomes

  1. To compare the efficacy of repeat pulmonary vein isolation (PVI) with PFA or point-by-point RF ablation.

    12-month incidence of AF/AFl/AT recurrence.

    Time frame: 12 months

Secondary outcomes

  1. To compare the efficacy of repeat pulmonary vein isolation (PVI) with PFA or point-by-point RF ablation.

    24-month incidence of AF/AFl/AT recurrence.

    Time frame: 24 months

  2. Repeat PVI within 12 and 24 months of randomization

    Repeat PVI

    Time frame: 12 and 24 months

  3. AF burden with and without 3 months blanking period

    Proportion of cumulative time in AF divided by the total time accrued over follow-up

    Time frame: 12 and 24 months

  4. Change in quality of life

    As measured by EuroQol-5D-5L questionnaire

    Time frame: 12 and 24 months

  5. Change in quality of life as affected by AF

    As measured by AF Effect On Quality-Of-Life (AFEQT) questionnaire

    Time frame: 12 and 24 months

  6. AF hospitalisation / urgent visit

    Hospitalization/urgent visit for atrial fibrillation

    Time frame: 12 and 24 months

  7. Cost-effectiveness

    Cost-effectiveness

    Time frame: 12 and 24 months

  8. Rate of ischemic stroke

    Rate of ischemic stroke

    Time frame: 12 and 24 months (efficacy)

  9. Complications of ablation

    Death, stroke, pericarditis, cardiac tamponade, vascular access complications etc.

    Time frame: 0-30 days post ablation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2028, 48 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Jan 10, 2024
StartActual
Sep 20, 2024
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06199180
Responsible party
Sponsor
First posted
Jan 10, 2024
Start date
Sep 20, 2024
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Dec 10, 2024

Study contacts

Yuri Blaauw, Dr.
Contact
y.blaauw01@umcg.nl
+31503616161
Nick van Vreeswijk, drs.
Contact
n.l.van.vreeswijk@umcg.nl
+31503616161
Yuri Blaauw, Dr.
principal investigator · UMCG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion